Vertex Pharmaceuticals reported third quarter 2026 total revenue of $3.44 billion, exceeding analyst estimates of $3.42 billion. Non-GAAP diluted EPS reached $4.76, beating the $4.36 expectation, driven by continued cystic fibrosis (CF) market leadership and growing contributions from non-CF product launches.

Key Highlights

  • Total revenue increased 12% year-over-year, supported by strong CF therapy demand and $157 million in combined revenue from newly launched therapies CASGEVY and JOURNAVX.
  • Vertex raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion, incorporating approximately $540 million to $550 million from non-CF treatments.
  • Operating expenses surged due to the $9.0 billion net cash acquisition of Crinetics Pharmaceuticals and commercial scaling for the renal franchise ahead of the November 30 PDUFA date for povetacicept.